To evaluate the safety and efficacy of the Magmaris bioresorbable magnesium scaffold in patients with acute coronary syndrome (ACS) and compare outcomes directly with drug-eluting stents (DES).
Key Findings:
No significant difference in TLF between Magmaris and DES (7.5% vs. 5.3%, p = 0.21).
Higher target-lesion revascularization (TLR) rates with Magmaris (6.8% vs. 3.0%, p = 0.019).
Low scaffold thrombosis rates observed (0.83% in single-arm analyses).
Procedural success rate was high at 98.49%.
Interpretation:
Magmaris shows low ST rates but higher TLR compared to DES, indicating a need for further improvements in magnesium scaffold technology to enhance patient outcomes.
Limitations:
Limited number of studies and patients included in the analysis, which may affect the robustness of the findings.
Heterogeneity in study designs and patient populations could influence the overall conclusions drawn.
Conclusion:
While Magmaris demonstrates potential in ACS, its comparative safety and efficacy against DES remain uncertain, necessitating further research to clarify its role in clinical practice.
by Simon Wölbert, Pablo F. F. Escrihuela-Branz, Stephanie Gladys Kühne, Andrea Patrignani, Mauro Chiarito, Jan Torzewski, Philip W. J. Raake, Dario Bongiovanni
